The question of a DHEA dose comes after the reason for treatment. An amount from a forum or study is not a personal starting point. Diagnosis, goal, route and planned monitoring matter.
A possible medical use is narrowly defined
The Endocrine Society describes a supervised DHEA trial in selected women with primary adrenal insufficiency and persistent symptoms despite otherwise optimized hormone replacement. After an initial six months, it should be discontinued when sustained benefit is absent. [1]
This is not a general recommendation for tired healthy people or a substitute for essential prescribed adrenal hormones. A specific disease managed by a care team differs from a self-assumed hormone gap.
Local prasterone is a different application
The EMA describes prasterone, also called DHEA, in the prescription medicine Intrarosa for local treatment of certain vulvar and vaginal symptoms after menopause. Application, population and contraindications are product-specific. [2]
This local medicinal use does not establish a corresponding oral capsule amount. Results from different routes must not be transferred merely because the active substance has the same name.
| Question | What the plan should answer |
|---|---|
| Indication | Which confirmed condition or specific problem is being treated? |
| Product and route | Which exact preparation is intended for which use? |
| Monitoring | Which symptoms and, where appropriate, laboratory values are reviewed when? |
| Stopping or adjustment | What happens with insufficient benefit or unwanted effects? |
Laboratory values need context
For the selected DHEA replacement trial, the guideline specifies monitoring morning DHEA-S before the next dose. [1] This does not create a general goal of raising every value as high as possible.
Bring complete reports with units, reference range and collection time. State whether a preparation had already been used before sampling. A lone screenshot without this information can easily encourage a wrong conclusion.
Do not escalate independently based on intuition
Failure of a hoped-for effect should not automatically lead to a larger serving. Changes to prescribed treatment belong in consultation. With a self-purchased product, first establish whether an appropriate indication exists at all.
For personal preparation, combine all hormone products and supplements in one list and record the timing of new symptoms. This is more useful than switching between internet dosing schedules. Availability in another country is not personal safety evidence or confirmation of local legal status.
Frequently asked questions
Is there a universal DHEA starting dose?
A general self-treatment plan cannot be justified.
Are local prasterone products interchangeable with oral preparations?
No. Purpose, application and evidence differ.
Must a trial continue indefinitely despite insufficient benefit?
No. Planned review belongs in the medical decision.
Is a high laboratory value automatically a good result?
No. Benefit and safety need assessment together.
Read more: DHEA basics and evidence and Assessing symptoms separately from hormone findings.
Sources
[1] Endocrine Society: Primary Adrenal Insufficiency, recommendations 3.11–3.13. [2] EMA: Intrarosa. Sources linked in the text; date: September 30, 2026. Not individual dosing, prescribing or legal product clearance.
